Skip to main content
  1. Home
  2. Emerging Tech
  3. Photography
  4. News

The FAA is approving an average of 300 commercial drone certifications a day

Add as a preferred source on Google

Nearly 23,000 people in the U.S. are now certified to operate a drone commercially — and the number of registered drones for both consumer and commercial applications totals around 550,000. While the commercial pilot certification standards didn’t begin until the end of the summer, the number of drone registrations for both business and hobby purposes has more than tripled since January.

The Federal Aviation Administration recently shared data showing an average of 300 commercial certifications have been issued each weekday since the new regulations took effect on Aug. 31, totaling 22,959 commercial drone pilots as of Dec. 5. The new regulations require commercial drone operators using a quadcopter over 0.55 pounds to pass a test at a local testing center before taking flight. Before that, commercial drone users were required to have a full pilot’s license.

Recommended Videos

The new regulations — and the which test runs about $150 to take — also added a few safety nets, prohibiting flight over crowds as well as flight where the operator cannot see the drone, though pilots can apply for waivers. The regulations apply to anyone using a drone professionally, whether that’s for a photography business or to inspect industrial sites.

While hobbyists using drones don’t need to pass that same test, those handling drones over a half pound still need to register their aircraft. As of September, the FAA had registered over 550,000 drones. That’s more than three times the number of registered drones from the start of the year.

While 23,000 or so commercial licenses were issued, the FAA says about 28,000 people submitted applications. According to the FAA, the test is designed to measure basics, such as whether the pilot knows how to read aeronautical charts to recognize prohibited airspace. While registering a drone can be done online, the commercial testing has to take place at one of the 689 FAA-approved locations throughout the U.S.

Hillary K. Grigonis
Hillary never planned on becoming a photographer—and then she was handed a camera at her first writing job and she's been…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more